STUDY OBJECTIVE: We sought to determine the effect of severe obstructive sleep apnea (OSA) on long-term outcomes after myocardial infarction. We hypothesized that severe OSA was associated with lower event-free survival rate after ST-segment elevation myocardial infarction (STEMI). METHODS: A total of 120 patients underwent an overnight sleep study during index admission for STEMI. Severe OSA was defined as apnea hypopnea index (AHI) ≥ 30, and non-severe OSA defined as AHI < 30. RESULTS: Among the 105 patients who completed the study, 44 (42%) had severe OSA and 61 (58%) non-severe OSA. The median creatine kinase level and mean left ventricular systolic function were similar between the 2 groups. None of the 105 study patients had received treatments for OSA. Between 1- and 18-month follow-up, the severe OSA group incurred 1 death, 2 reinfarctions, 1 stroke, 6 unplanned target vessel revascularizations, and 1 heart failure hospitalization. In contrast, there were only 2 unplanned target vessel revascularizations in the non-severe OSA group. The incidence of major adverse events was significantly higher in the severe OSA group (15.9% versus 3.3%, adjusted hazard ratios: 5.36, 95% CI: 1.01 to 28.53, p = 0.049). Kaplan-Meier event-free survival curves showed the event-free survival rates in the severe OSA group was significantly worse than that in the non-severe OSA group (p = 0.021, log-rank test). CONCLUSION: 42% of the patients admitted with STEMI have undiagnosed severe OSA. Severe OSA carries a negative prognostic impact for this group of patients. It is associated with a lower event-free survival rate at 18-month follow-up.
STUDY OBJECTIVE: We sought to determine the effect of severe obstructive sleep apnea (OSA) on long-term outcomes after myocardial infarction. We hypothesized that severe OSA was associated with lower event-free survival rate after ST-segment elevation myocardial infarction (STEMI). METHODS: A total of 120 patients underwent an overnight sleep study during index admission for STEMI. Severe OSA was defined as apnea hypopnea index (AHI) ≥ 30, and non-severe OSA defined as AHI < 30. RESULTS: Among the 105 patients who completed the study, 44 (42%) had severe OSA and 61 (58%) non-severe OSA. The median creatine kinase level and mean left ventricular systolic function were similar between the 2 groups. None of the 105 study patients had received treatments for OSA. Between 1- and 18-month follow-up, the severe OSA group incurred 1 death, 2 reinfarctions, 1 stroke, 6 unplanned target vessel revascularizations, and 1 heart failure hospitalization. In contrast, there were only 2 unplanned target vessel revascularizations in the non-severe OSA group. The incidence of major adverse events was significantly higher in the severe OSA group (15.9% versus 3.3%, adjusted hazard ratios: 5.36, 95% CI: 1.01 to 28.53, p = 0.049). Kaplan-Meier event-free survival curves showed the event-free survival rates in the severe OSA group was significantly worse than that in the non-severe OSA group (p = 0.021, log-rank test). CONCLUSION: 42% of the patients admitted with STEMI have undiagnosed severe OSA. Severe OSA carries a negative prognostic impact for this group of patients. It is associated with a lower event-free survival rate at 18-month follow-up.
Authors: Daniel J Gottlieb; Gayane Yenokyan; Anne B Newman; George T O'Connor; Naresh M Punjabi; Stuart F Quan; Susan Redline; Helaine E Resnick; Elisa K Tong; Marie Diener-West; Eyal Shahar Journal: Circulation Date: 2010-07-12 Impact factor: 29.690
Authors: Anne Kaltoft; Henning Kelbaek; Leif Thuesen; Jens Flensted Lassen; Peter Clemmensen; Lene Kløvgaard; Thomas Engstrøm; Hans E Bøtker; Kari Saunamäki; Lars R Krusell; Erik Jørgensen; Hans-Henrik Tilsted; Evald H Christiansen; Jan Ravkilde; Lars Køber; Klaus F Kofoed; Christian J Terkelsen; Steffen Helqvist Journal: J Am Coll Cardiol Date: 2010-08-17 Impact factor: 24.094
Authors: Andrew Cassar; Timothy I Morgenthaler; Ryan J Lennon; Charanjit S Rihal; Amir Lerman Journal: J Am Coll Cardiol Date: 2007-09-17 Impact factor: 24.094
Authors: Charlotte M S Detremmerie; Susan W S Leung; Paul M Vanhoutte Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-07-30 Impact factor: 3.000
Authors: R Nisha Aurora; Ciprian Crainiceanu; Daniel J Gottlieb; Ji Soo Kim; Naresh M Punjabi Journal: Am J Respir Crit Care Med Date: 2018-03-01 Impact factor: 21.405